[Slow-release @entity33483 for maintenance therapy of XXXX ].

@entity1 @entity4521 @entity4784 @entity4783 @entity2072 @entity33483 @entity1245 @entity1286 @entity284
INTRODUCTION: In Austria, @entity284 , @entity4783 as well as oral slow-release @entity1286 are used for the treatment of @entity4784 . This controlled examination marks the first time that oral slow-release @entity33483 is applied for maintenance therapy in opioid dependent subjects. METHODS: In order to evaluate the effectiveness of this psychopharmacological medication, we examined @entity1 over a three-week period. Outcome measures were retention rate, additional consumption and the evaluation of opioid withdrawal 24 hours after the last oral medication. RESULTS: Sixty-seven @entity1 were included; sixty-four @entity1 completed the study, representing a retention rate of 94%. During the three-week period, a significant improvement in well-being and a significant reduction in @entity4521 , @entity2072 and @entity1245 craving (p < 0.0001) was evaluated. Furthermore, there was a significant reduction of additional consumption of @entity1245 in supervised urinalysis. Additional consumption of @entity2072 remained unchanged. Laboratory results showed a significant reduction of CK over the course of investigation. DISCUSSION: The high retention rate of 94% implies a good acceptance and efficacy of the substance. The reduced CK is consistent with a reduction in intravenous application of illegal substances. However, randomized double-blind, double-dummy studies with oral slow-release @entity1286 are needed in order to meet criteria for evidence based medicine.
